Rehmannia

Rehmannia (Rehmannia glutinosa): A Comprehensive Reference

1. Identity and Botanical Description

Taxonomy and Names

Rehmannia glutinosa (RG) is a fundamental herb in traditional Chinese medicine belonging to the Orobanchaceae family. Older botanical classifications placed it in the family Scrophulariaceae, and some literature still uses that designation. The genus is named for Joseph Rehmann (1788–1831), a physician in St. Petersburg, while the species epithet glutinosa means "glutinous," "sticky," or "viscous." Unlike the majority of broomrapes, R. glutinosa is not parasitic and is capable of independent photosynthesis.

The plant is known by a variety of names across cultures and commercial contexts. In traditional Chinese medicine it bears the name shēng dì huáng (生地黄) and is often sold as gān dì huáng (干地黄), gān meaning "dried." Other names include Chinese Foxglove, Earth Emperor Root, Di Huang, and — in its processed form — Shú Dì Huáng (熟地黄). In traditional herbal literature, it is commonly referred to as Radix Rehmanniae. In Korean traditional medicine it is called Saeng-Ji-Whang (raw) or Sook-Ji-Whang (processed), and in Japanese practice Jio or Juku-Jio.

Geographic Origin and Plant Morphology

The plant prefers well-drained ground along roadsides, mountain slopes, and trail sides, and its native range encompasses East Asia, northern China, and Korea. It bears large purplish-pink flowers. The root (rhizome) is the primary medicinal part, though leaves are also used to a lesser extent.

Principal Forms and Preparations

Three distinct medicinal forms of R. glutinosa are officially recognized and have markedly different pharmacological profiles based on their preparation:

• Fresh Rehmannia Root (Xiān Dì Huáng): The fresh root has the effect of clearing away heat and promoting salivation, and of removing heat from the blood to stop bleeding.
• Dried Rehmannia Root (Shēng Dì Huáng): The dried rhizome has the effect of removing pathogenic heat from blood, nourishing Yin, and promoting the production of body fluids.
• Prepared (Processed) Rehmannia Root (Shú Dì Huáng): The prepared root — traditionally steamed in rice wine — has the effect of nourishing Yin, supplementing the blood, and benefiting the marrow.

The main chemical components in fresh R. glutinosa are iridoid glycosides and sugars, with iridoids absent in the fresh form. Modern commercial preparations include standardized capsules, tablets, liquid extracts, tinctures, decoctions, and dried root powder. Rehmannia is also a foundational ingredient in many classical multi-herb formulas, most prominently Liuwei Dihuang (Six-Ingredient Pill with Rehmannia).

Traditional Rehmannia formulations often steamed the processed roots, partly because oligosaccharides such as stachyose and verbascose can produce flatulence when unprocessed.

2. Traditional and Historical Use

Traditional Chinese Medicine

Rehmannia glutinosa is one of the 50 fundamental herbs used in traditional Chinese medicine. As early as 100 A.D., Rehmannia glutinosa was recorded in Shennong's herbal classic (Shennong Bencao Jing) as a plant of Scrophulariaceae. In TCM, Rehmannia has been used for over 2,000 years.

The herb is categorized within TCM primarily as a Yin-nourishing tonic. It is taken to nourish Yin and invigorate the kidney in traditional Chinese medicine and has been ascribed very high medicinal value. Rehmannia glutinosa is fundamentally thought of as a drug for nourishing Yin and tonifying the kidney, which — in TCM theory — has the functions of storing essence, dominating growth, development and reproduction, and regulating water metabolism, with a close relationship to the neuroendocrine system.

Traditional indications cover a broad range of conditions. It has traditionally been employed to treat conditions such as Yin deficiency, blood deficiency, fevers, anemia, and fatigue. It has also been used in the management of night sweats, hot flashes, dizziness, and dry mouth — all associated in TCM with Yin deficiency. The raw form was specifically used for heat-clearing purposes, to clear heat, cool the blood, nourish Yin, treat febrile diseases or bleeding disorders, and address dry mouth, irritability, and insomnia.

Classical Multi-Herb Formulas

Rehmannia has rarely been used as a single-herb remedy in classical practice; it most commonly appears as the principal herb in compound formulas. The Liuwei Dihuang pill (Liu Wei Di Huang Wan) is a classical Chinese medicine prescription created by Qian Yi during the Song dynasty that tonifies the kidney. This formula consists of six herbs: Rehmannia glutinosa, Cornus officinalis, Dioscorea opposita, Poria cocos, Alismatis rhizoma, and Moutan cortex, and has a long history in treating multiple diseases in Asia. Rehmanniae Decoction of Six Ingredients has been indicated as a remedy for geriatric diseases for a long time. RG has also been used in TCM to treat aging-related conditions including dementia and senile diseases.

Korean and Japanese Traditional Medicine

Rehmannia glutinosa is a common traditional herbal medicine used for the treatment of aging-related diseases in Korea and China, and is extensively used under the name Di-Huang in Chinese traditional medicine for treating diabetes mellitus. In Korean traditional medicine (Hanbang), it appears in classical formulas such as Kyung-Ok-Ko, used to support vitality and address conditions of Yin deficiency.

3. Key Constituents and Active Compounds

In recent decades, a great number of chemical and pharmacological studies have been done on Rehmannia glutinosa. More than 70 compounds, including iridoids, saccharides, amino acids, inorganic ions, and other trace elements, have been found in the herb. The principal bioactive classes are described below.

Iridoid Glycosides

Iridoid glycosides constitute the most pharmacologically significant class of compounds in R. glutinosa. A number of chemical constituents, including iridoids, phenethyl alcohol glycosides, cyclopentanoid monoterpenes, and norcarotenoids, have been reported from the fresh or processed roots.

Catalpol is the predominant and most extensively studied iridoid glycoside. Catalpol, also known as catalpinoside, is the main active ingredient of Rehmannia glutinosa. It has anti-inflammatory and antioxidant properties and exerts neuroprotective effects, improving neurocognitive function. The iridoid glycosides are considered to be the main pharmacological components of R. glutinosa, and catalpol (CAT) has been identified as having the best cytoprotective effect; it is the most major component of the iridoid glycosides.

Additional key iridoid glycosides identified in RG include rehmaglutin A, B, C, and D, as well as jioglutin A, B, and C, and jioglutolide. Other bioactive molecules identified include caffeic acid, geraniol, 5-hydroxytryptamine, melatonin, and rhodioloside.

Phenylethanol Glycosides (Phenylethanoid Glycosides)

Rehmannia glutinosa Libosch mainly contains the major components of iridoids (e.g., catalpol) and phenylethanol glycosides (e.g., verbascoside), is clinically beneficial to the liver and kidney, and is applied to promote circulation of the blood. Acteoside (also called verbascoside) is a key phenylethanol glycoside that has attracted particular research attention for its renal-protective and anti-inflammatory properties. Acteoside, the main component of Rehmannia glutinosa with anti-inflammatory and anti-immune effects, can improve urinary protein excretion.

Polysaccharides and Oligosaccharides

Rehmannia glutinosa has gained research interest particularly for its polysaccharides (RGPs). Accumulating evidence confirms that RGPs are complex heteropolysaccharides with a wide array of pharmacological activities, including immunomodulation, anti-aging, hypoglycemic, and antitumor effects — many of which are mediated through gut microecology modulation.

Polysaccharides — biopolymers composed of several monosaccharides connected by glycosidic bonds — are the main active functional components of RG. They are typically extracted and purified from the roots and stems of RG and have a relative molecular weight of 4 × 10³ to 5 × 10⁴ Da.

The oligosaccharides found in R. glutinosa include stachyose, raffinose, and verbascose. These oligosaccharides may exert immune modulation via effects on gastrointestinal microbiota and, like inulin and other studied oligosaccharides, are referred to as prebiotics because of their support of beneficial intestinal bacteria. The oligosaccharides and ionone glycosides in Rehmannia are both credited with hepatoprotective activities.

Additional Constituents

Rehmannia also contains the ionone glycosides dihydroxy-β-ionone and trihydroxy-β-ionone, three phenethylalcohol glycosides, one furfural derivative, feruloyl ajugol and ajugol isomers, the carotenoid glycosides neo-rehmannioside and oxyrehmonioside, a polyoxygenated triterpene named glutinolic acid, and two aeginetic acid quinovosides. Sugar alcohols including mannitol are also present, as are free sugars (sucrose, galactose, fructose, glucose) and various amino acids.

4. Mechanisms of Action

Overview

Studies show that Rehmannia glutinosa and its active principles possess wide pharmacological actions on the blood system, immune system, endocrine system, cardiovascular system, and the nervous system. The pharmacological effects arise from multiple mechanisms acting simultaneously across different organ systems.

Anti-Inflammatory Mechanisms

Catalpol is a primary driver of Rehmannia's anti-inflammatory activity. Research in animal models indicates that it suppresses pro-inflammatory transcription factors. Rehmannia glutinosa reduces kidney inflammation in diabetic nephropathy rats via the TLR4/MyD88/NF-κB pathway. At a cellular level, Rehmannia glycoside D has been shown to reduce the levels of pro-inflammatory cytokines IL-6 and IL-1β released by M1 microglia, while increasing anti-inflammatory cytokines IL-4 and IL-10 released by M2 microglia. Polysaccharides from RG (RGP) have attracted attention for their antioxidant, anti-inflammatory, and immune-enhancing properties, and have been found to regulate the Keap1/Nrf2 and NF-κB/TLR4 signaling pathways.

Neuroprotective Mechanisms

Elevated serotonin and BDNF levels by catalpol significantly protect against depression and neurodegeneration. Administration of catalpol for 14 days produces significant antidepressant effects in a mouse model of depression through the serotonin pathway, and the antidepressant effects may be related to repair of the hypothalamic-pituitary-adrenal (HPA) axis and increased expression of brain-derived neurotrophic factor (BDNF).

In the context of spinal cord injury, CAT has been found to have a restorative effect on lower limb motor function in rats with spinal cord injury; further investigation found that it inhibits apoptosis and protects neurons by reducing endoplasmic reticulum stress through inhibition of CHOP and GRP78 expression.

Antidiabetic and Metabolic Mechanisms

The antioxidant and free radical scavenging activity of catalpol are key mechanisms for exhibiting neuroprotection, anti-atherosclerosis, cardioprotective, and antidiabetic activity. Researchers reported that catalpol activated AMPK/PGC-1α/TFAM signaling, which augments mitochondrial biogenesis in skeletal muscle, thereby increasing glucose uptake. Catalpol has also demonstrated increased mitochondrial biogenesis and activation of the PI3K/Akt pathway for an insulin-sensitizing effect.

Renal-Protective Mechanisms

In animal models of renal fibrosis, Rehmannia and its extracts have been found to modulate fibrotic signaling. Rehmannia glutinosa leaves total glycoside inhibited the expression of α-SMA, TGF-β1, Smad3, and Smad4 in kidney tissues of db/db mice and in human renal tubular epithelial (HK-2) cells. Catalpol, an iridoid glucoside from the root of R. glutinosa, manifests anti-inflammatory, antioxidant, antiapoptotic, and antifibrotic properties.

Immunomodulatory Mechanisms

Although immunosuppressive fractions have been identified in Rehmannia, overall the plant is demonstrated to be immune modulating, as are iridoid glycosides in general, one of the main active molecular groups in Rehmannia. Rehmannia glutinosa polysaccharide significantly enhanced the proliferation of T and B lymphocytes of the spleen in aged mice, phagocytosis of peritoneal macrophages, and cytotoxic effects against cancer cell lines in preclinical work.

Hematopoietic Mechanisms

Rehmannia glutinosa polysaccharide can stimulate hematopoiesis function in mice, and Rehmannia glutinosa oligosaccharide can activate hematopoietic microenvironment cells and promote the secretion of hematopoiesis growth factors (CFU-GM, CFU-E, and BFU-E) to enhance proliferation of hematopoietic cells.

Cardiovascular Mechanisms

The cardiovascular protective effect of catalpol is linked to PI3K/Akt, apelin/APJ, and Jak-Stat pathways. Antihypertensive effects have been documented in preclinical research as well, though the specific molecular pathway mediating this has not been fully elucidated in clinical settings.

5. Scientific Evidence by Health Area

5.1 Kidney Disease (Chronic Kidney Disease and Glomerulonephritis)

The most substantive human clinical evidence for Rehmannia relates to kidney disease, particularly glomerulonephritis and chronic kidney disease (CKD).

Randomized Controlled Trial — Chronic Glomerulonephritis: A total of 479 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and randomly assigned to a treatment group (Rehmannia glutinosa acteosides, two 200-mg capsules, twice daily; and irbesartan, one 150-mg tablet, once daily) or a control group (irbesartan, one 150-mg tablet, once daily). After 8 weeks of treatment, the treatment group showed a mean reduction in 24-hour proteinuria of 36.42% compared to baseline, which was significantly higher than the mean reduction of 27.97% in the control group (P = 0.0278). Adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and control group (1.2%, P = 0.3724). This trial concluded that the combination of Rehmannia glutinosa acteosides and irbesartan can reduce proteinuria more effectively than irbesartan alone.

IgA Nephropathy: A smaller clinical study examined acteoside in IgA nephropathy. Serum Th22 cells and urine total protein of patients with IgA nephropathy were measured before and after six months of treatment with Rehmannia glutinosa acteoside or valsartan. Results showed that the proteinuria and Th22 lymphocytosis of patients with IgA nephropathy significantly improved after combination treatment of R. glutinosa acteoside and valsartan, compared with valsartan monotherapy. The acteoside dose in this study was 0.8 g/d, combined with valsartan 80–160 mg/d.

Preclinical Evidence: In an adenine-induced murine model of CKD, administering 5 mg/kg catalpol to BALB/c mice significantly ameliorated altered body and kidney weight, water intake, urine volume, and concentrations of urea and creatinine in plasma, as well as creatinine clearance and the albumin-to-creatinine ratio.

Evidence Strength: There is one sizable (n=479) randomized controlled trial supporting the use of Rehmannia acteosides as an adjunct to an angiotensin receptor blocker for proteinuria reduction in glomerulonephritis. The overall human evidence base remains limited, and larger independent trials are needed.

5.2 Diabetes and Glucose Metabolism

Some trials suggest benefits in managing type 2 diabetes, improving insulin sensitivity, and reducing blood glucose levels. However, the published human evidence largely comprises preclinical and small-scale studies.

Animal Studies: In db/db mice (a model of spontaneous type 2 diabetes), Rehmannia glutinosa leaves total glycoside (DHY) significantly decreased fasting blood glucose, insulin, total cholesterol, and triglyceride levels, and improved kidney injury markers. In a study investigating the mechanism of catalpol on blood glucose, a T2DM model was constructed by intraperitoneal injection of streptozotocin into Sprague-Dawley rats, which were treated for 28 days; changes in body weight, fasting blood glucose, insulin, and lipid levels were observed.

Mechanism: Catalpol activated AMPK/PGC-1α/TFAM signaling, which augments mitochondrial biogenesis in skeletal muscle, thereby increasing glucose uptake and ATP production, pointing to a plausible antidiabetic mechanism.

Evidence Strength: Evidence is predominantly preclinical (animal and cell-based). People use rehmannia for kidney disease, anemia, obesity, and diabetes, but there is no good scientific evidence to support these uses. High-quality human randomized controlled trials for diabetes as a primary endpoint are lacking.

5.3 Osteoporosis and Bone Metabolism

Rehmannia, particularly within the Liuwei Dihuang formula, has accumulated substantial preclinical and some clinical data in osteoporosis research.

Rehmannia and TCM formulas containing it are widely used to treat osteoporosis patients. In modern pharmacological studies, the water extract of RR has been shown to improve bone mineral density (BMD) and increase cortical bone thickness and trabeculation of the bone marrow spaces. Liuwei Dihuang Pill has also been shown to have preventive and therapeutic effects on primary osteoporosis through promoting bone formation.

The therapeutic mechanism of Liuwei Dihuang pill in osteoporosis is complicated, including the balance between osteoclasts and osteoblasts, anti-inflammation, and modulation of kinase pathways. A metabolomics study showed that Rehmanniae Radix Praeparata extract protects against glucocorticoid-induced osteoporosis primarily by intervening in steroid hormone biosynthesis pathways.

Evidence Strength: The wide acceptance of TCM such as Liuwei Dihuang pill still faces problems related to unclear efficacy and mechanism in scientific scope, including purity, dosage, and safety. Most osteoporosis data come from animal models; clinical trials that have been conducted largely involve the multi-herb formula rather than Rehmannia as an isolated ingredient, making attribution difficult. Because the preparation is often used in combination with other agents, it is difficult to attribute any benefits to R. glutinosa alone.

5.4 Neuroprotection and Neurological Conditions

The neuroprotective potential of catalpol has been explored extensively in preclinical models of several neurological conditions.

Cerebral Ischemia: Rehmannia Decoction is a representative prescription for ischemic stroke, and its efficacy in the treatment of ischemic stroke has been confirmed by both clinical and experimental studies, and it is still used in clinical treatment of cerebral apoplexy. In a rat model of stroke, the protective effect of catalpol administered intranasally on stroke-induced brain injury and its mechanisms on the oxidative stress pathway Nrf2/HO-1 and apoptosis were investigated using middle cerebral artery occlusion (MCAO).

Spinal Cord Injury: An iridoid glycoside extract of catalpol (CAT) has antioxidant, antiapoptotic, and neuroprotective pharmacological effects. CAT was found to have a restorative effect on the lower limb motor function of rats with spinal cord injury when treating by gavage for 30 days.

Depression: Treatment with catalpol (5, 10, or 20 mg/kg) for 14 days reduced mice's depressive-like behavior in a depression model; catalpol increased the content of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in mice's brains, while exhibiting minimal influence on levels of norepinephrine and dopamine. This indicates that catalpol has an antidepressant-like effect mediated by the central serotonergic system.

Evidence Strength: All neurological evidence to date is from animal and in vitro models. No adequately powered human clinical trials evaluating Rehmannia or catalpol as standalone interventions for neurological conditions have been published. This area is currently preclinical only.

5.5 Immune Modulation

Extensive in vitro and in vivo studies have established polysaccharides as principal bioactive constituents responsible for the therapeutic effects of Rehmannia glutinosa. These RGPs exhibit a broad and promising spectrum of pharmacological properties, including immunomodulation, anti-inflammatory, antitumor, anti-aging, and metabolic regulatory activities, many of which are mediated through gut microbiota modulation.

Evidence Strength: Immunomodulatory evidence is predominantly from animal and cell culture experiments. Despite its traditional significance, scientific studies on RG's therapeutic mechanisms remain limited, and its underlying pharmacological pathways are not extensively elucidated. No human clinical trials specifically examining immune outcomes as primary endpoints have been identified.

5.6 Hematopoiesis and Anemia

TCM has used Rehmannia for blood deficiency and anemia for centuries. Research suggests that Rehmannia glutinosa polysaccharide can stimulate hematopoiesis function by administration of certain doses in mice. Human clinical data specifically on Rehmannia for anemia remain sparse and are largely embedded in polyherbal formula studies.

5.7 Cardiovascular Health and Blood Pressure

Preclinical studies have examined antihypertensive effects of R. glutinosa. Some scholars have suggested that Rehmannia Radix Praeparata (RR) has an antihypertensive effect. Catalpol's cardiovascular protective effect is linked to the PI3K/Akt, apelin/APJ, and Jak-Stat pathways. However, robust human evidence for cardiovascular outcomes is absent.

5.8 Anti-Tumor Activity

Preclinical research has examined Rehmannia polysaccharides and catalpol in cancer cell lines. Catalpol has produced a significant reduction in cell proliferation and an increase in apoptosis in different cancer conditions in vitro. Crude hot water extracts of Rehmannia glutinosa showed dose-dependent inhibition on the proliferation of hepatocellular carcinoma cell lines (H-4-II-E and HA22T/VGH cells), and inhibited proliferation and stimulated p53-mediated apoptosis in HCC cells in vitro. These findings are exclusively in vitro and do not constitute evidence of clinical anticancer efficacy.

6. Body Systems Associated with Rehmannia

Based on both traditional use and scientific investigation, Rehmannia glutinosa has been associated with the following body systems:

• Renal System: Wide pharmacological actions on the blood system, immune system, endocrine system, cardiovascular system, and the nervous system have been documented. Renal-protective effects are the most clinically corroborated.
• Endocrine and Metabolic System: Blood glucose regulation through AMPK-mediated pathways; modulation of steroid hormone biosynthesis relevant to osteoporosis.
• Nervous System: Neuroprotective, antidepressant, and anti-neurodegenerative properties via serotonergic, HPA axis, and BDNF mechanisms — currently preclinical only.
• Immune System: Immunomodulation via polysaccharide-mediated effects on lymphocyte proliferation and gut microbiota.
• Hematopoietic System: Stimulation of bone marrow and hematopoietic growth factors.
• Musculoskeletal System: Bone metabolism and osteoporosis prevention, primarily via the Liuwei Dihuang formula.
• Cardiovascular System: Anti-inflammatory and antioxidant protection; preliminary antihypertensive evidence.

7. Dosage Forms and Doses Reported in Studies

Clinical studies are largely lacking to inform definitive dosage recommendations. The following doses have been used in specific studies and are reported as-is from those sources:

• Chronic Glomerulonephritis (RCT): Rehmannia glutinosa acteosides: two 200-mg capsules twice daily (total 800 mg/day), alongside irbesartan 150 mg once daily, for 8 weeks.
• IgA Nephropathy (clinical study): Rehmannia glutinosa acteoside 0.8 g/d, combined with valsartan 80–160 mg/d.
• Chronic Glomerulonephritis (Rehmannia leaf study): One study has shown benefit in chronic glomerulonephritis in human subjects at a dose of 400 mg twice a day, improving proteinuria.
• Catalpol (anti-depressant, mouse): Treatment with catalpol at 5, 10, or 20 mg/kg for 14 days in a murine depression model.
• Catalpol (TBI, rat): Catalpol 10 mg/kg administered via intravenous injection 1 hour post-trauma and then once daily for 3 consecutive days in a rat traumatic brain injury model.
• Catalpol (CKD, mouse): 5 mg/kg catalpol administered to BALB/c mice for 4 weeks (except weekends) in an adenine-induced CKD model.
• Traditional decoction (general reference): Rehmannia is generally considered safe even at high doses up to 50 g/day in traditional preparations — though this reflects traditional empirical practice rather than formally controlled dosing.

Common nonprescription polyherbal products contain varying amounts of Rehmannia root extract, and no standardized dose has been established for dietary supplement use in Western regulatory frameworks.

8. Safety Considerations and Drug Interactions

Observed Adverse Effects

Minor and transient adverse reactions have been reported and include gastrointestinal reactions (e.g., diarrhea, abdominal pain), edema, heart palpitations, fatigue, and vertigo. In the large glomerulonephritis RCT, adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and the control group (1.2%).

Traditional formulations may suffer from issues such as variability in potency, potential for adverse effects, and lack of standardization, which limits their acceptance in modern evidence-based medicine.

Contraindications

Chronic liver disease and gastrointestinal disorders, including diarrhea, are noted as conditions warranting avoidance. Rehmannia has traditionally been used as an emmenagogue, and there is no published or anecdotal evidence regarding the use of Rehmannia in pregnancy or lactation.

Drug Interactions

Antidiabetic Drugs: Rehmannia might decrease blood sugar, and there is concern that taking rehmannia with other medications for diabetes might cause blood sugar to decrease too much. Monitoring of blood sugar is advised, and the dose of diabetes medication might need to be changed.

Perioperative Considerations: Because rehmannia might affect blood glucose levels, it might interfere with blood sugar control during and after surgery. Use is recommended to be stopped at least 2 weeks before a scheduled surgery.

CYP450 Enzyme System: Animal research has indicated that water extracts of Rehmannia glutinosa may influence the activity of hepatic cytochrome P450 enzymes (specifically CYP3A, CYP2E1, and CYP1A2), which could theoretically affect the metabolism of drugs processed by these enzymes. This finding, documented in rat studies, has not been confirmed in humans.

Toxicity Reduction in Combination: Combinational application of Panax notoginseng (PN) and Rehmannia glutinosa (RG) has been observed to weaken the toxicity of Tripterygium wilfordii (a potentially hepatotoxic and nephrotoxic herb) according to clinical application of TCM.

Standardization Challenges

Research on Rehmannia polysaccharides is compounded by the challenges common to plant polysaccharides, exacerbated by their significant structural variability. This heterogeneity stems from multiple extrinsic factors such as plant origin, processing methods, and extraction protocols, leading to substantial variation in key structural parameters like molecular weight and monosaccharide composition. This variability poses challenges for ensuring consistent potency and safety across commercially available preparations.

9. Overall Evidence Assessment

Limited high-quality, large-scale clinical trials exist, warranting further research to confirm efficacy and safety. The available human evidence is strongest — though still limited in scope — for the use of Rehmannia acteosides as an adjunct to standard-of-care angiotensin receptor blockers in reducing proteinuria in glomerulonephritis. For most other proposed indications (neuroprotection, antidiabetic action, immune modulation, hematopoiesis, cardiovascular effects), the evidence base remains at the preclinical level — animal and cell culture studies — with no adequately powered, placebo-controlled, randomized human trials.

Despite the significant role RG plays in traditional medicine, there are notable limitations and challenges in its application. The traditional use of RG relies on empirical knowledge and formulations, often without a clear understanding of specific mechanisms or bioactive targets. Additionally, traditional formulations may suffer from issues such as variability in potency, potential for adverse effects, and lack of standardization, which limits their acceptance in modern evidence-based medicine and the development of RG-based therapeutic drugs. These limitations have restricted RG's application in contemporary medical practices, underscoring the need for scientific validation and mechanistic elucidation.

References

• Zhang RX, Li MX, Jia ZP. Rehmannia glutinosa: review of botany, chemistry and pharmacology. J Ethnopharmacol 2008;117(2):199–214. PubMed
• Zhang RX et al. Rehmannia glutinosa: Review of botany, chemistry and pharmacology. ScienceDirect (Journal of Ethnopharmacology, 2008)
• Exploring the Therapeutic Potential of Rehmannia glutinosa: A Network Pharmacology and Molecular Docking Analysis Across Multiple Diseases. PMC 2025
• Multiple Biological Effects of an Iridoid Glucoside, Catalpol, and Its Underlying Molecular Mechanisms. PMC 2020
• Effect and Mechanism of Catalpol on Remyelination via Regulation of the NOTCH1 Signaling Pathway. PMC 2021
• Catalpol as a Component of Rehmannia glutinosa Protects Spinal Cord Injury by Inhibiting Endoplasmic Reticulum Stress-Mediated Neuronal Apoptosis. PMC 2022
• Feasibility of Catalpol Intranasal Administration and Its Protective Effect on Acute Cerebral Ischemia in Rats. PMC 2022
• Rehmannia glutinosa DC.–Lilium lancifolium Thunb. in the treatment of depression: a comprehensive review and perspectives. PMC 2024
• Catalpol Ameliorates Oxidative Stress and Neuroinflammation after Traumatic Brain Injury in Rats. PubMed 2022
• The Active Ingredient Catalpol in Rehmannia glutinosa Reduces Blood Glucose in Diabetic Rats via the AMPK Pathway. Dove Medical Press 2024
• Catalpol Attenuates Oxidative Stress and Inflammation via Mechanisms Involving Sirtuin-1 Activation and NF-κB Inhibition in Experimentally-Induced Chronic Kidney Disease. PMC 2023
• Qiu H et al. Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial. Phytother Res 2014;28(1):132–6. PubMed
• Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy. PMC 2018
• Preventive effects of the Rehmannia glutinosa Libosch and Cornus officinalis Sieb herb couple on chronic kidney disease rats via modulating intestinal microbiota. PMC 2022
• Rehmannia glutinosa Libosch ameliorates diabetic nephropathy via the TLR4/MyD88/NF-κB signalling pathway. ScienceDirect 2025
• Protective effects and mechanisms of Rehmannia glutinosa leaves total glycoside on early kidney injury in db/db mice. PubMed 2020
• Advancement in treating osteoporosis with traditional Chinese medicine Liuwei Dihuang pill. Frontiers in Musculoskeletal Disorders 2025
• Metabolomics Profiling Reveals Rehmanniae Radix Preparata Extract Protects against Glucocorticoid-Induced Osteoporosis. PMC 2019
• Rehmannia glutinosa polysaccharides: a review on structural features, pharmacological potential, and advanced delivery systems. Frontiers in Nutrition 2026
• Rehmannia glutinosa Polysaccharides: Optimization of the Decolorization Process and Antioxidant and Anti-Inflammatory Effects. PMC 2023
• Compatibility with Panax notoginseng and Rehmannia glutinosa Alleviates the Hepatotoxicity and Nephrotoxicity of Tripterygium wilfordii. PMC 2018
• Dì huáng (Rehmannia glutinosa) Monograph. Restorative Medicine
• Chinese Foxglove (Rehmannia glutinosa) Uses, Benefits & Dosage. Drugs.com Natural Products
• Rehmannia: Overview, Uses, Side Effects, Precautions, Interactions, Dosing. WebMD Vitamins & Supplements
• Rehmannia: Health Benefits, Side Effects, Uses, Dose & Precautions. RxList
• Rehmannia glutinosa. Wikipedia
• Rehmannia glutinosa — A Phyto-Pharmacological Review. Pharmacologyonline 2010
• Acteoside protects podocyte against apoptosis through regulating AKT/GSK-3β signaling pathway in db/db mice. BMC Endocrine Disorders 2023
• Catalpol ameliorates CFA-induced inflammatory pain by targeting spinal cord and peripheral inflammation. PMC 2022